3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Diabetic Nephropathy: new trials by email Literature Review of Diabetic Nephropathy trials Research Report on Diabetic Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Participants With Diabetic Kidney Disease LY2382770, Placebo - Diabetic Kidney Disease, Diabetic Nephropathy | Phase 2 | Terminated | Eli Lilly and Company | 417 | 2010-07-01 | 2019-09-17 |
| Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy FG-3019, Placebo - Type 2 Diabetes Mellitus, Diabetic Nephropathy | Phase 2 | Terminated | Kyntra Bio | 46 | 2009-02-01 | 2019-02-22 |
| Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria Alagebrium, Placebo - Diabetes Mellitus, Type 1, Diabetic Nephropathy | Phase 2 | Terminated | Synvista Therapeutics, Inc | 80 | 2007-11-01 | 2009-01-30 |
Diabetic Nephropathies (3) · Diabetes Mellitus, Type 1 (2) · Diabetes Mellitus, Type 2 (2) · Kidney Failure, Chronic (1) · Renal Insufficiency, Chronic (1)
Diabetes Complications (3) · Diabetes Mellitus (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Glucose Metabolism Disorders (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Autoimmune Diseases (2) · Immune System Diseases (2) · Chronic Disease (1)
alagebrium (1) · pamrevlumab (1)
Eli Lilly and Company (1) · Kyntra Bio (1) · Synvista Therapeutics, Inc (1)
Australia (2) · United States (2) · Czechia (1) · Denmark (1) · France (1) · Hungary (1) · Israel (1) · Puerto Rico (1)